Response Biomedical’s Q3 Sales up 14 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Response Biomedical today reported that its third-quarter revenues rose 39 percent, while its net loss fell around 14 percent.

The genetic test maker brought in revenues of C$2 million (US$1.9 million) for the three-month period ended Sept. 30, compared to revenues of C$1.5 million in the period last year.

Most of that revenue boost came from the firm’s clinical products business, which increased 62 percent to around C$1.7 million compared with approximately C$1 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.